GlassScriptPhysician profile
Matthew K Sanger
NPI 1639119910
$2,947.22
in general payments reported to CMS, 2019-2025
29 companies · $606 in 2025
The $606 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $41.17 · 2021: $363 · 2022: $602 · 2023: $293 · 2024: $667 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,552.95 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $410.15 | 2021-2025 | Farxiga, Lokelma |
| Bard Peripheral Vascular, INC. | $391.31 | 2019-2022 | |
| Amgen INC. | $270.75 | 2021-2025 | Krystexxa, Tavneos |
| Philips North America LLC | $218.44 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $212.12 | 2022-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $186.59 | 2021-2025 | |
| Vifor Pharma, INC. | $142.45 | 2021-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $119.28 | 2021-2025 | Jynarque |
| Cook Medical LLC | $110.31 | 2020-2023 | Zilver Ptx, Zilver Vena |
| Abbott Laboratories | $105.24 | 2022 | |
| Fresenius USA Marketing, INC. | $100.37 | 2022-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $98.68 | 2023-2025 | Tarpeyo |
| Akebia Therapeutics INC | $84.12 | 2022-2025 | Vafseo, Auryxia |
| Horizon Therapeutics Plc | $62.00 | 2022-2023 | Krystexxa |
| Travere Therapeutics, INC. | $55.26 | 2022-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.99 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $44.27 | 2022-2024 | Lupkynis |
| Medtronic, INC. | $43.47 | 2021 | |
| Alexion Pharmaceuticals, INC. | $35.80 | 2021-2022 | |
| Nxstage Medical, INC. | $33.72 | 2024 | |
| Janssen Pharmaceuticals, INC | $29.73 | 2019 | |
| Ardelyx, INC. | $26.72 | 2024 | Ibsrela |
| Ani Pharmaceuticals, INC. | $19.07 | 2025 | Purified Cortrophin Gel |
| W. L. Gore & Associates, INC. | $18.47 | 2022 | |
| Argon Medical Devices, INC. | $17.86 | 2022 | |
| Angiodynamics, INC. | $15.81 | 2019 | |
| Opko Pharmaceuticals, LLC | $15.34 | 2021 | |
| Novo Nordisk INC | $14.46 | 2024 | Wegovy |
| Lilly USA, LLC | $14.44 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Sanger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.